| (19) |
 |
|
(11) |
EP 2 394 636 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
18.01.2012 Bulletin 2012/03 |
| (43) |
Date of publication: |
|
14.12.2011 Bulletin 2011/50 |
| (22) |
Date of filing: 28.05.2010 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME RS |
| (71) |
Applicant: Novagali Pharma S.A. |
|
91000 Evry (FR) |
|
| (72) |
Inventors: |
|
- Garrique, Jean-Sébastien
91370 Verrières le Buisson (FR)
- Lallemand, Frédéric
94260 Fresnes (FR)
- Heier, Jeffrey
Boston MA 02114 (US)
|
| (74) |
Representative: Icosa |
|
83 avenue Denfert-Rochereau
75014 Paris
75014 Paris (FR) |
|
| |
|
| (54) |
Method for treating retinal conditions using an intraocular tamponade |
(57) Composition comprising at least one fatty acid glycerol ester for use in or after
a vitrectomy procedure, said composition being bioresorbable, being injectable in
the vitreous cavity, having a density below 1, more preferably comprised between 0.90
and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension
of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not
susceptible to emulsify into droplets when injected; method for treating a retinal
disorder involving the use of said composition.